The FDA has accepted the new drug application (NDA) for SH 201, the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers
Additional analyses from a negative Phase III clinical trial of Gammagard Liquid/Kiovig (intravenous immunoglobulin), from Baxter, in people with mild...
The aim of this review is to summarize the state of the art of this approach and the latest novelties regarding detection, prognosis and surveillance of bladder cancer.
Foundation Medicine, Inc. announced that the FDA approved FoundationOne Liquid CDx, the Company’s comprehensive pan-tumor liquid biopsy test.
This retrospective study aims to deepen the understanding and clarify possible mechanisms of osimertinib 1st line resistance in comparison to the 2nd line by examining NGS results of 30 patients who developed resistance to osimertinib.
The FDA has approved Gammagard Liquid 10% [Immune Globulin Infusion (Human)] as a treatment for Mmultifocal Motor Neuropathy (MMN). This is...
Medical - for cuts, bites, abrasions and insect stings. Personal hygiene - for douching, dandruff; and spots and pimples.
Shire plc announces positive topline Phase III results for the SAHARA study, a global, multi-center, randomized, double-blind, placebo-controlled, partial crossover...
Rare Disease Therapeutics, Inc. the producer of orphan pharmaceuticals for the treatment of rare diseases, announced that they have received...
Takeda announced that the FDA has approved Gammagard Liquid[Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)